Can I stop taking adagrasib after taking it for ten months?

Adagrasib is a targeted drug mainly used to treat patients with KRAS G12C mutant non-small cell lung cancer (NSCLC). It reduces the proliferation and spread of tumor cells by inhibiting the activity of KRAS G12C mutants and has shown significant therapeutic effects in multiple clinical studies. However, the decision as to whether the drug can be discontinued after 10 months of treatment still needs to be made based on the patient's specific condition.

The duration of treatment with adagrasib usually depends on the patient's tumor response and disease progression. For some patients, significant tumor control or even partial remission may occur after treatment with adagrasiib. In this case, the doctor may consider reducing the dose or discontinuing the medication to evaluate whether the patient can remain stable without the medication. However, this decision needs to be carefully considered and the treatment plan must be individualized based on the patient's specific circumstances.

Although adagrasib can effectively inhibit the growth of KRAS G12C mutant tumors, the complexity of cancer means that complete discontinuation of the drug may bring certain risks. Some patients may experience disease relapse or drug resistance after discontinuation of treatment. Therefore, during treatment, patients need to undergo regular imaging examinations and biomarker testing to assess tumor progression. If the tumor shows signs of recurrence, treatment may need to be restarted or another treatment option may be chosen.

The decision to discontinue a drug is usually made by doctors based on the patient's clinical response, drug resistance, tumor progression, and the patient's overall health. If the patient's tumor is effectively controlled during 10 months of treatment and there are no signs of recurrence, the doctor may consider reducing the frequency of drug use or gradually discontinuing the drug. However, even after stopping the medication, patients still need to monitor their condition closely and stay in contact with their doctor to ensure any signs of recurrence are detected promptly.

Therefore, whether the drug can be discontinued after 10 months depends on the patient's individual response and the status of the tumor. Before discontinuing medication, you should fully communicate with your doctor to understand the possible risks and benefits, and develop a reasonable monitoring and adjustment plan.

References：https://www.krazati.com/